You just read:

BerGenBio to Present Overview of Phase II Clinical Trial Portfolio Combining Bemcentinib With KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe

News provided by

BerGenBio ASA

Mar 22, 2018, 03:21 ET